Entremed (ENMD)

[C_Peptide]

Re: topical panzem

As long-timers know, I've been an advocate of topical 2ME2 for years as a way to get around the first-pass metabolism problem. Another company, PR Pharmaceuticals is developing 2ME2 in a monthly injectible depot formulation for the indication of pulmonary arterial hypertension. I've mentioned earlier how I think the IP aspects of that will play out.

There are problems with topical 2ME2 for treating systemic disease, based on the amount that would be needed. Although the idea is the same as estriadiol in a contraceptive patch, the dose is orders of magnitude larger.

For inflammatory/angiogenic skin diseases, like psoriasis, eczema, maybe discoid lupus, and probably even cutaneous T-cell lymphoma, where local concentrations can be much higher than the systemic, a panzem cream or ointment has a good chance of being more effective and more safe than anything out there.

I've also always advocated the idea of suppository 2ME2 delivery as an ...er... end-run around the first pass metabolism, but Americans tend to be pathologically squeamish about that. Europeans don't seem to mind. It is the ideal anti-emetic route. Swallow a pill for nausea and vomiting? How dumb is that?

Best Regards,
C-Peptide